Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Salvage therapy with azacitidine for pediatric acute myeloid leukemia with t(16;21)(p11;q22)/FUS‐ERG and early relapse after allogeneic blood stem cell transplantation: A case report

Abstract Acute myeloid leukemia (AML) with FUS‐ERG has a poor prognosis regardless of allo‐hematopoietic stem cell transplantation (HSCT). Maintenance therapy such as azacitidine after allo‐HSCT for AML with FUS‐ERG may be clinically meaningful.

Bibliographic Details
Main Authors: Dai Keino, Takashi Mori, Mizuho Morimoto, Kensuke Kondo, Tetsuya Mori, Akitoshi Kinoshita
Format: Article
Language:English
Published: Wiley 2019-11-01
Series:Clinical Case Reports
Subjects:
acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
azacitidine
FUS‐ERG
salvage therapy
t(16;21)(p11;q22)
Online Access:https://doi.org/10.1002/ccr3.2461

Internet

https://doi.org/10.1002/ccr3.2461

Similar Items